Table 1 Clinical characteristics of... | American Society of Hematology

Table 1

Clinical characteristics of B-CLL patients

Patient	Sex/age, y	Stage*	CD38/ZAP-70†	Ig status
1	M/59	B/II	+/+	ND
2	M/65	B/II	+/−	ND
3	F/84	A/I	+/+	ND
4	F/69	B/II	+/−	ND
5	M/62	B/II	+/+	ND
6	M/80	A/0	−/−	Mutated
7	M/62	A/0	−/−	Mutated
8	M/78	A/0	+/+	Unmutated

Patient	Sex/age, y	Stage*	CD38/ZAP-70†	Ig status
1	M/59	B/II	+/+	ND
2	M/65	B/II	+/−	ND
3	F/84	A/I	+/+	ND
4	F/69	B/II	+/−	ND
5	M/62	B/II	+/+	ND
6	M/80	A/0	−/−	Mutated
7	M/62	A/0	−/−	Mutated
8	M/78	A/0	+/+	Unmutated

No patient received therapy.

ND indicates not determined.

According to Binet et al²² and Rai et al²³ criteria.

The coexpression of CD38 and ZAP-70 is now determined routinely in all B-CLL samples as this analysis apparently has prognostic value.^24,25